Predictors of 30-day readmission rate after total gastrectomy in patients with gastric malignancy.

Authors

null

Miguel Salazar

Cleveland Clinic, Cleveland, OH

Miguel Salazar , Estefania Gauto , Shristi Upadhyay Upadhyay Banskota , Pedro Palacios , Trilok Shrivastava , Binav Baral , Pierre Alexander Rodriguez Alarcon , Maha Elsebaie , Nabin Khanal

Organizations

Cleveland Clinic, Cleveland, OH, John H. Stroger Jr. Hospital of Cook County, Chicago, IL, John H. Stroger Hospital of Cook County, Chicago, IL, Mayo Clinic Jacksonville Gastroenterology & Hepatology, Jacksonville, FL, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, John H. Stroger Jr. Hospital of Cook County Internal Medicine, Chicago, IL, Creighton University School of Medicine, Omaha, NE

Research Funding

No funding received
None

Background: Total gastrectomy with lymph node dissection is curative for early gastric malignancy which accounts for 1.5% of cancer cases in the U.S. Readmissions are common postoperatively, and are associated with increased morbidity, mortality, hospital costs and decreased quality of life. We hence aim to identify incidence, impact and independent predictors for readmission in patients who underwent total gastrectomy in gastric malignancy. Methods: We conducted a retrospective cohort study of the 2017 National Readmission Database (NRD) of adult patients readmitted within 30 days after an index admission for total gastrectomy with a concomitant diagnosis of gastric malignancy. T-test was used for continuous variables and chi square test was used for categorical variables. Multivariate regression was used to identify predictors for unplanned readmissions. ICD 10 codes were used to identify diagnoses and procedures. Results: A total of 1,779 patients with gastric malignancy underwent total gastrectomy. The 30-day readmission rate was 18.5%. Main causes for readmission were sepsis, ventricular fibrillation, recurrent STEMI. Readmitted patients were more likely to be on chemotherapy. (40.1% vs 27.2%; P<0.01) and more likely to be discharged to a skilled facility (13.5% vs 17.9%; P<0.01). The total health care in-hospital economic burden of readmission was $6.5 million in total charges and $25 million in total costs. Independent predictors of readmission were major bleeding, respiratory failure requiring mechanical ventilation, peripheral parenteral nutrition, history of non-alcoholic hepato-steatosis, and prolonged length of stay. Conclusions: Readmissions after gastrectomy in patients with gastric malignancies are associated with lower in-hospital mortality yet pose a substantial economic burden on healthcare. The lower mortality might be explained by the relatively stable course and lower comorbidities of patients who become eligible for discharge after surgery. Further studies are suggested. Modifiable risk factors like malnutrition and sepsis warrant special attention to decrease readmissions and improve overall outcomes.

Common causes of readmission (n=329).

Diagnosis
N (%)
ICD10-CM code
Pulmonary embolism
3.7
I2699
Sepsis, unspecified organism
3.4
A419
COPD exacerbation with pneumonia
1.6
J440
Independent Predictors of 30-Day Readmission
Variable
Adjusted Odds Ratio

(95% Confidence Interval)
P value
In-Hospital Procedures

Peripheral Parenteral Nutrition


2.41 (1.11-5.25)


0.02
Comorbidities

NASH


2.92 (1.17-7.29)


0.02
In-Hospital Complications

Mechanical Ventilation

Major Bleeding


1.62 (1.01-2.69)

11.51 (4.92-26.90)


0.05

<0.01

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2021 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr e16109)

DOI

10.1200/JCO.2021.39.15_suppl.e16109

Abstract #

e16109

Abstract Disclosures

Similar Abstracts

First Author: Miguel Salazar

First Author: Omid Yazdanpanah

First Author: Shristi Upadhyay Upadhyay Banskota